During a recent government meeting, Araceli Naranjo, representing the GMP manufacturing side, provided an in-depth overview of the CAR T therapy process and the operations of the Cellular Therapy Production Center (CTPC). Naranjo emphasized the extensive training and dedication of her team, which is responsible for manufacturing T cells used in CAR T therapy, a groundbreaking treatment for certain cancers.

Naranjo detailed the step-by-step process of CAR T therapy, beginning with leukopheresis, where blood is drawn to isolate specific cells. These cells are then genetically modified using a CAR T lentivirus before being expanded in the GMP facility. The final product is prepared for infusion into patients through various methods, including intraventricular and intravenous administration.

The CTPC, located on the fourth floor of the Beckman building, features six production suites, four of which are currently operational. Naranjo highlighted the facility's stringent cleanliness standards, adhering to ISO 7 classification, which requires personnel to wear specialized protective equipment to maintain a sterile environment. Established in 2010, the CTPC plays a crucial role in advancing CAR T therapy, targeting various cancer markers such as CD19, CD33, and HER2.

This presentation underscored the importance of the manufacturing side of CAR T therapy, showcasing the meticulous processes involved in developing this innovative treatment that holds promise for patients battling cancer.